이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 전립선암에 대한 인간 칼리크레인-2(hK2)를 표적으로 하는 악티늄-225 표지 항체 JNJ-69086420에 대한 연구

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

진행성 전립선암에 대한 인간 칼리크레인-2(hK2)를 표적으로 하는 악티늄-225 표지 항체 JNJ-69086420의 1상 연구

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.

연구 개요

연구 유형

중재적

등록 (실제)

144

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • Mayo Clinic Arizona
    • California
      • Duarte, California, 미국, 91010
        • City of Hope
    • Florida
      • Jacksonville, Florida, 미국, 32224
        • Mayo Clinic in Florida
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • University of Chicago
    • Louisiana
      • Metairie, Louisiana, 미국, 70006
        • East Jefferson General Hospital
      • New Orleans, Louisiana, 미국, 70112
        • Tulane University Hospital & Clinics
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, 미국, 68130
        • XCancer Omaha / Urology Cancer Center
    • New York
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • Case Western Reserve University
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • University of Utah Huntsman Cancer Institute

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • For Part 1, Part 2, Part 3: Metastatic castration resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma (adenocarcinoma with small-cell or neuroendocrine features is allowed) with prior exposure to at least one androgen receptor (AR) targeted therapy (for example [e.g.], abiraterone acetate, enzalutamide, apalutamide, darolutamide). In addition: Part 1: prior taxane or other chemotherapy is acceptable but not required. Part 2a: prior taxane or other chemotherapy required, Part 2b: no prior taxane or other chemotherapy, Part 2c: mCRPC that has progressed after prior treatment with lutetium Lu-177 vipivotide tetraxetan, with or without prior chemotherapy, Part 3: prior taxane or other chemotherapy is acceptable but not required & For Part 4a: metastatic HSPC, For Part 4b: disease that can be treated with less than or equal to (<=) 5 radiation fields and no visceral metastases
  • Parts 1, 2 & 3: Prior orchiectomy or medical castration, or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase. This criterion does not apply to Part 4
  • Palliative radiotherapy (e.g. soft tissue lesions) must be completed greater than (>) 2 weeks prior to start of study drug except for palliative radiotherapy for pain (e.g., bone pain), which may be used any time prior to first dose
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ functions as reflected in laboratory parameters

Exclusion Criteria:

  • Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, samarium, or other radioconjugate therapy, other systemic anti-neoplastic therapy <=30 days prior to the first dose of study drug except for luteinizing hormone-releasing hormone agonists/antagonists or GnRH agonists/antagonists. Novel androgen axis drugs <=14 days prior to the first dose of study drug. In addition: Part 2b: Must not have received prior treatment with chemotherapy (eg, docetaxel) or poly ADP ribose polymerase (PARP) inhibitors, Part 2c: Prior treatment with lutetium Lu-177 vipivotide tetraxetan is required, but must have been completed >42 days prior to first dose of study drug, Part 3: Must not have received prior treatment with JNJ-78278343, Part 4: Must not have received ADT or AR-targeted therapy less than or equal to (<=) 56 days prior to first dose of study drug
  • Known history of myelodysplastic syndrome, leukemia, or hematological malignancy with features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any timepoint
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, radiation tissue fibrosis, or peripheral neuropathy)
  • Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients and protein therapeutics. For Part 3, known allergies, hypersensitivity, or intolerance to JNJ-78278343 or its excipients or protein therapeutics
  • Active or chronic hepatitis B or hepatitis C infection

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 1: Dose Escalation

Participants will receive JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.

Participants will receive JNJ-69086420.

다른 이름들:
  • 악티늄-225-DOTA-h11B6
실험적: Part 2: Dose Expansion

Participants in one or more cohorts will receive JNJ-69086420 at the RP2D(s) determined in Part 1.

Participants will receive JNJ-69086420.

다른 이름들:
  • 악티늄-225-DOTA-h11B6
실험적: Part 3: Combination Therapy

Participants will receive JNJ-69086420 at the determined RP2D(s) and fixed dose of JNJ-78278343.

Participants will receive JNJ-69086420.

다른 이름들:
  • 악티늄-225-DOTA-h11B6

Participants will receive JNJ-78278343.

실험적: Part 4: HSPC Expansion

Participants with HSPC will receive JNJ-69086420 at the RP2D(s) in Part 4(a), and JNJ-69086420 following stereotactic body radiation therapy in Part 4(b).

Participants will receive JNJ-69086420.

다른 이름들:
  • 악티늄-225-DOTA-h11B6

Participants will receive stereotactic body radiaition therapy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
기간: Up to 2 years and 4 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 2 years and 4 months
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
기간: Up to 2 years and 4 months

Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 2 years and 4 months
Number of Participants with AEs by Severity
기간: Up to 2 years and 4 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 2 years and 4 months

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants with Prostate Specific Antigen (PSA) Response
기간: Up to 2 years and 4 months

PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline and that is subsequently confirmed.

Up to 2 years and 4 months
Overall Response Rate (ORR)
기간: Up to 2 years and 4 months

ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3).

Up to 2 years and 4 months
Maximum Observed Serum Concentration/Radioactivity (Cmax) of JNJ-69086420
기간: Up to 2 years and 4 months

Cmax is defined as the maximum observed serum concentration/radioactivity of JNJ-69086420.

Up to 2 years and 4 months
Time to Reach Maximum Observed Serum Concentration/Radioactivity (Tmax) of JNJ-69086420
기간: Up to 2 years and 4 months

Tmax is defined as time to reach maximum observed serum concentration/radioactivity of JNJ-69086420.

Up to 2 years and 4 months
Area Under the Serum Concentration-time Curve From Time Zero to t Time (AUC[0-t]) of JNJ-69086420
기간: Up to 2 years and 4 months

AUC(0-t) is defined as the area under the serum concentration-time curve from time zero to t of JNJ-69086420.

Up to 2 years and 4 months
Number of Participants With Anti-JNJ-69086420 Antibodies
기간: Up to 2 years and 4 months

Number of participants with anti-JNJ-69086420 antibodies will be assessed to evaluate the potential immunogenicity.

Up to 2 years and 4 months
Part 3: Serum Concentration of JNJ-78278343
기간: Up to 2 years and 4 months

Venous blood samples will be collected for assessment of serum concentrations of JNJ-78278343.

Up to 2 years and 4 months
Part 3:Number of Participants With Anti-JNJ-78278343 Antibodies
기간: Up to 2 years and 4 months

Number of participants with anti-JNJ-78278343 antibodies will be assessed to evaluate the potential immunogenicity.

Up to 2 years and 4 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 11월 12일

기본 완료 (추정된)

2026년 12월 8일

연구 완료 (추정된)

2026년 12월 30일

연구 등록 날짜

최초 제출

2020년 11월 20일

QC 기준을 충족하는 최초 제출

2020년 11월 20일

처음 게시됨 (실제)

2020년 11월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다